We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CVRx Meets Enrollment Goal for Heart Failure Study

CVRx Meets Enrollment Goal for Heart Failure Study

June 9, 2014

Minneapolis-based devicemaker CVRx said Monday it has completed enrollment of the Barostim HOPE4HF heart failure study. The implantable Barostim neo device triggers the body’s own natural blood flow regulation system to treat heart failure and hypertension, according to the company.

The randomized, controlled clinical trial will evaluate the performance of Barostim in 140 patients suffering from chronic heart failure with advanced systems, CVRx spokesman Tom Moore told Device Daily Bulletin. The Barostim neo currently is being clinically evaluated for the treatment of hypertension in the U.S.

The Barostim neo received CE Mark approval for the treatment of hypertension on in December 2011, said CVRx Chief Financial Officer John Brintnall. The HOPE4HF trial is being conducted to gain an additional CE Mark for the treatment of heart failure and to provide the basis for designing a larger U.S. trial to gain FDA approval for a heart failure indication, he added.

Meanwhile, the French health ministry has selected Barostim neo for resistant hypertension as one of five investigator-initiated studies it will fund in 2014. The investigator-initiated study to evaluate the incremental cost-effectiveness of Barostim for the treatment of resistant is sponsored by the Nancy University Hospital in France. The study will randomize 128 patients to receive optimal medical management or Barostim neo plus optimal medical management at 13 hypertension centers of excellence across France, CVRx said. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Commercial Operations

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing